The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.